Our infectious disease vaccine platform builds on proven COVID-19 vaccine R&D and develops mRNA vaccines for rabies, RSV, influenza, VZV, HSV, and more. We aim to establish a 60-day rapid response platform: based on the original COVID-19 strain, we can complete design, small-scale production, and validation within 60 days of a new variant sequence release, then scale up. We will continue to accumulate mRNA vaccine R&D experience and strive to build a 60-day rapid response platform for any emerging or sudden infectious disease within 3-5 years, leveraging the efficiency of mRNA synthesis, cell-free production, and rapid capacity expansion.

Successfully developed a COVID-19 vaccine and established a 60-day rapid response platform for COVID-19 variants.